Key result
Physiologically based pharmacokinetic modeling can potentially assist therapeutic decision making for digoxin dosing in patients undergoing continuous venovenous hemodiafiltration.
Why the study?
Guidelines specifying appropriate digoxin dosing in patients undergoing continuous venovenous hemodiafiltration are lacking.
Case Report (n=1)
Physiologically based pharmacokinetic modeling can potentially assist in point-of-care dosing decisions for digoxin in patients undergoing continuous venovenous hemodiafiltration.
PBPK modeling may aid digoxin dosing in CVVHDF; leaves open need for prospective validation before practice change.
We describe the case of a patient on continuous venovenous hemodiafiltration with atrial fibrillation with rapid ventricular response and hypotension requiring vasopressor use, which warranted digoxin therapy. In the absence of guidelines specifying appropriate digoxin dosing in patients undergoing continuous venovenous hemodiafiltration, anecdotal evidence-guided digoxin dosing was performed for this patient using plasma digoxin concentration-based therapeutic drug monitoring. We use this case to demonstrate the potential role of physiologically based pharmacokinetic modeling in assisting therapeutic decision making.
No takes yet. Share an insight, caveat, or question.
Srinivasan et al. (2019) conducted a case report in Atrial fibrillation with rapid ventricular response and hypotension on continuous venovenous hemodiafiltration (n=1). Physiologically based pharmacokinetic modeling for digoxin dosing was evaluated. Physiologically based pharmacokinetic modeling can potentially assist therapeutic decision making for digoxin dosing in patients undergoing continuous venovenous hemodiafiltration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: